Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis - Wikidata - awgldk - TriplyDB

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

http://www.wikidata.org/entity/Q28271140

about

Dimethyl fumarate for multiple sclerosis Dimethyl fumarate for multiple sclerosis Laquinimod for multiple sclerosis Laquinimod for multiple sclerosis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Retinal Cell Degeneration in Animal Models Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy Biomarkers of therapeutic response in multiple sclerosis: current status Observational data: Understanding the real MS world.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort Activities of daily living and lesion position among multiple sclerosis patients by Bayes network.Interferons, signal transduction pathways, and the central nervous system.Drug therapy for multiple sclerosis.Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.Inhibition of NR2B-Containing N-methyl-D-Aspartate Receptors (NMDARs) in Experimental Autoimmune Encephalomyelitis, a Model of Multiple Sclerosis Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE Estimating typical multiple sclerosis disability progression speed from clinical observations.Predictors of disability worsening in clinically isolated syndrome.A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.Associations of Lifestyle, Medication, and Socio-Demographic Factors with Disability in People with Multiple Sclerosis: An International Cross-Sectional Study.A longitudinal model for disease progression was developed and applied to multiple sclerosis.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?The evidence for hypoperfusion as a factor in multiple sclerosis lesion development.Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Beta-interferon exposure and onset of secondary progressive multiple sclerosis.NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS.UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.Assessing treatment response to interferon-β: is there a role for MRI?Treatment of experimental autoimmune encephalomyelitis by codelivery of disease associated Peptide and dexamethasone in acetalated dextran microparticles Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

P2860

Q24186433-3C593958-6819-49A6-9A35-5956E3EFB3FC Q24197602-3E4678DC-B599-4F5B-8FB1-DCEE41F423DD Q24198180-9A3C05B7-5D49-4C93-BD7A-7070F63A9EDE Q24200527-6FC5E5DF-BF86-4B59-93BA-3B0F62F7BEDE Q24202108-975F0628-84EC-459A-8D1F-A84AD3AD5F2B Q26771160-CD3F87DE-4AB8-4CC1-89A9-29798BE25501 Q27011473-1F2B3DE1-864B-4DFB-867A-85EFA106D11E Q27012726-09E17502-5740-4209-B752-707C1982E76B Q30249781-BB88AE21-1AEC-40D9-831D-94E01E73B300 Q30869048-DF1E20A6-BB67-4194-B7F0-4072A3A27F1F Q33755345-B7CDA9B6-864E-4EED-AD4F-6AB70C063E47 Q33847487-AADE9B5C-3EAC-4E58-9759-7D03AA97F9AF Q33937065-ED11BC22-6A5D-4EB0-9566-6D591B3CD797 Q33988186-24E0F138-FFB3-4A84-A671-7D657FA37970 Q33990246-43B88385-9A6D-4C02-9725-12211CCA4D19 Q34069978-1562A83F-D53A-4287-90BA-30F1C935EA7D Q34146191-C376F166-F914-4E87-996C-5C5E0EB3A9C6 Q34314312-3470350A-2BDF-4DD3-BD1B-9C47ACFDA1D3 Q34737478-107E422C-7984-4B93-81C1-6A1A71C8D933 Q35087742-13D734EB-349B-448F-90FC-38C6198B823C Q35348224-F28754C0-FE79-41E4-AB21-24A757BD7A17 Q35619185-E995736B-D91D-404F-9D14-A95180D8ECDB Q35747637-50B9BD47-A028-4643-B475-9BBF52AE31B1 Q35866381-137712C7-CD7B-4A77-BA08-9EB736A1EE5E Q35902505-58C5DB23-7172-432B-9192-B614EFACE049 Q36045080-BC60A3E9-D8C4-446E-A653-B0A790B5594A Q36112918-4D43A39E-6DF2-4452-956F-CC83F50897A1 Q36275639-BD24962B-DEF5-42C2-BAE8-0BABFBDC51D8 Q36396476-3973AB34-E32B-4556-A0E0-0B6E28B1A6B4 Q36831144-56412992-2875-46EE-B469-5A2F9CAD9FDC Q36839629-742CC4CA-08B4-482C-989D-BAE8283C65B0 Q36968664-001D57AD-67AD-4614-A26E-23769BDF773F Q36975701-80C36E8E-FC93-4E0D-945B-619A5E14FB23 Q37225075-F9F7A086-0DF5-494E-ACAF-D15A1D3DB885 Q37254889-01D91FE6-6318-44F9-96D4-3FDC7C3144A7 Q37517082-1AAA933D-B59F-4009-8A9F-0B94B2EFA482 Q37518057-2224E006-16DF-4F8B-B01F-B7F6E9323935 Q37714122-FE43575B-7827-4AB0-BB74-6A1561CF264E Q38101003-B6E1D98E-32CC-4BCC-B71D-B494C4847AE3 Q38107524-E3CED6EB-1A3D-4742-AD71-0C4183F28AF8

P2860

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

http://www.wikidata.org/entity/Q28271140

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Association between use of int ...... g-remitting multiple sclerosis

@ast

Association between use of int ...... g-remitting multiple sclerosis

@en

Association between use of int ...... g-remitting multiple sclerosis

@nl

type

label

Association between use of int ...... g-remitting multiple sclerosis

@ast

Association between use of int ...... g-remitting multiple sclerosis

@en

Association between use of int ...... g-remitting multiple sclerosis

@nl

prefLabel

Association between use of int ...... g-remitting multiple sclerosis

@ast

Association between use of int ...... g-remitting multiple sclerosis

@en

Association between use of int ...... g-remitting multiple sclerosis

@nl

P1433

Q28271140-1D95DF32-948A-4A12-BF43-8A101C8EB5D6

P1476

Q28271140-800CFB83-BC56-44AC-8629-0A1B26393C30

P2093

Q28271140-635259B7-DEBA-410B-B7A6-DED9AF260E96

Q28271140-91F892EA-510B-4CED-9107-CC987782F54A

Q28271140-BC6D9A6E-D2B9-4F50-9C7F-0C8398FDDC9D

Q28271140-D44CDB3B-49CF-4951-8FD5-B1BA26953ABA

Q28271140-E85878D0-0C3C-47B6-875F-796331B39E8C

Q28271140-F7709B3A-6E69-4388-9F07-06FD75DEE0A6

P304

Q28271140-C67DDB28-3272-47D9-B360-AC7649F2CFD6

P31

Q28271140-BC3F98AA-4B30-47BD-9EB7-235F84F559B9

P3181

Q28271140-BE641D0F-46FC-4A7C-AA11-D1DC48C2BCC7

P356

Q28271140-AC883A9B-F7F7-43DB-B3DB-8739FD898E56

P407

Q28271140-E2BC196E-50FE-4DB7-946A-79D045F5710E

P433

Q28271140-0F0458D6-E399-44C0-8A97-14B5EBDF573B

P478

Q28271140-39FFBCA4-508A-4771-98C1-0453D01689A5

P50

Q28271140-491303B3-82B6-470C-9D7B-C4D225C70BD2

Q28271140-4BFD4A21-4973-4AF6-A7CF-6EC5F3859161

Q28271140-7DBD0500-FB9A-49B6-AA90-656231152801

Q28271140-D1EA0C1E-7C35-4FB4-97E7-5504F2B6B449

P577

Q28271140-64E39A53-697A-4E70-AE0E-45A5C0A5A381

P5875

Q28271140-5825B71B-50F5-41A2-B535-4C28145DE9CA

P698

Q28271140-758DB5A3-9ACD-4EDB-B5CF-D63C00C5E8A4

P921

Q28271140-1F8C8ABB-8961-436E-9E65-325700BCD8C9

Q28271140-7269ABAA-1A64-4379-AB1E-3172597EBD61

Q28271140-754869E0-FBC1-442D-B354-FF2A22A30D76

Q28271140-D68669B3-8F3E-4B91-9A05-8BC0633B592F

P3181

P356

P1433

Journal of the American Medical Association

P1476

Association between use of int ...... g-remitting multiple sclerosis

@en

P2093

Afsaneh Shirani

http://www.w3.org/2001/XMLSchema#string

Charity Evans

http://www.w3.org/2001/XMLSchema#string

Joel Oger

http://www.w3.org/2001/XMLSchema#string

John Petkau

http://www.w3.org/2001/XMLSchema#string

Paul Gustafson

http://www.w3.org/2001/XMLSchema#string

Yinshan Zhao

http://www.w3.org/2001/XMLSchema#string

P304

247-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

939070

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.2012.7625

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

308

http://www.w3.org/2001/XMLSchema#string

P50

Mohammad Ehsanul Karim

Elaine Kingwell

Mia L van der Kop

P577

2012-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229152873

http://www.w3.org/2001/XMLSchema#string

P698

22797642

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis